Images in Clinical Hematology

Primary breast lymphoma in a male patient

**Estefanía López-Rodríguez**, Cristina Bujan-Lloret, Rosa María Álvarez-Pérez, José Manuel Jiménez-Hoyuela-García

Virgen del Rocío University Hospital, Seville, Spain

**A R T I C L E  I N F O**

Article history:
Received 9 October 2018
Accepted 18 February 2019
Available online 12 May 2019

Primary breast lymphoma is a rare neoplasm; it corresponds to 0.4–0.5% of breast tumors and is defined as the absence of concurrent widespread lymphoma, having no previous diagnosis of extramammary lymphoma. It is an infrequent tumor, as lymphoid tissue is absent in the mammary region. It is especially prevalent in females (95–100%), representing little more than a mere anecdote in males. The PET/CT can be useful in the initial staging, treatment response evaluation, and restaging of patients with primary breast lymphoma.

An 81-year-old man with a personal history of stage II colon adenocarcinoma that was completely resected in 2015, and who is currently in remission, has been diagnosed with a painless tumor in the left breast. The examination showed a 5- or 6-cm hard lump under the left nipple without palpable peripheral adenopathy. The left breast ultrasound demonstrated a hypoechoic and non-homogeneous mass measuring 35 mm in the lower inner quadrant. These sonographic findings were highly suspicious for malignancy. The histopathological analysis revealed a large B-cell lymphoma. Before the systemic therapy was started, a PET/CT was performed with ¹⁸F-FDG for extension study. The PET/CT with ¹⁸F-FDG images showed an area of increased radiopharmaceutical uptake located in the left breast with an approximate size of 5 × 5.5 × 4.7 cm (T × AP × CC) and it reached a maximum standardized uptake value (SUV) of 27.59 suggesting malignancy (Figure 1A). In the rest of the study, no other pathological uptake of the radiotracer was observed in the remaining lymph tissue examined (Figure 1B). The patient was treated with 4 cycles of CP (cyclophosphamide and prednisone) and radiotherapy. The post-treatment PET/CT showed a complete metabolic response (Figure 1C and D). The patient continues in clinical monitoring. We presented this case because of the singularity which this unusual type of tumor presents in men and the very reduced number of these cases described in the literature.

* Corresponding author at: Nuclear Medicine Department, Virgen del Rocío University Hospital, Av. Manuel Siurot s/n 41013, Seville, Spain. E-mail address: estefania.hr.86@gmail.com (E. López-Rodríguez).

https://doi.org/10.1016/j.htct.2019.02.004

2531-1379/© 2019 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1 – $^{18}$F-FDG PET/CT baseline (A, B) and $^{18}$F-FDG PET/CT post treatment (C, D). Images showing area of increased radiopharmaceutical uptake located in the left breast on transaxial fused images (A) that disappears after four cycle of chemotherapy (C). B and D are baseline and post-treatment maximum intensity projection (MIP) PET images demonstrating complete metabolic response.

Conflicts of interest

The authors declare no conflicts of interest.

References